---
title: "Rinvoq (upadacitinib) in rheumatoid arthritis: Dosing and administration questions"
description: "Dosing and administration questions on Rinvoq (upadacitinib) in rheumatoid arthritis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Treatment combinations, Dosing, Taking treatment, and Before treatment. Questions: Can RINVOQ be combined with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants? What is the RINVOQ dosage for rheumatoid arthritis? What should be done if RINVOQ tablet residue appears in the stool? Before starting RINVOQ, which vaccines should patients get? 1 further question follow. 5 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/dosing-and-administration"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Rinvoq (upadacitinib) in rheumatoid arthritis: Dosing and administration questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Rinvoq](https://www.rinvoqhcp.com/prescribinginfo)

## Treatment combinations

<a id="rinvoq-combination-restrictions"></a>

### Can RINVOQ be combined with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants?

> “Limitations of Use: RINVOQ is not recommended for use in combination with other Janus kinase (JAK) inhibitors, biologic disease-modifying antirheumatic drugs (bDMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.”

Source: [RINVOQ: RINVOQ® (upadacitinib) for Rheumatoid Arthritis, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatoid-arthritis#:~:text=Limitations%20of%20Use%3A%20RINVOQ%20is,such%20as%20azathioprine%20and%20cyclosporine.)

## Dosing

<a id="rinvoq-daily-tablet"></a>

### What is the RINVOQ dosage for rheumatoid arthritis?

> “RINVOQ is a 15 mg extended-release pill
> Take one pill 1 time a day with or without food
> Advise patients to avoid food or drink containing grapefruit during treatment with RINVOQ
> Swallow pill whole. Do not split, crush, or chew”

Source: [RINVOQ: RINVOQ® (upadacitinib) Dosing for RA, PsA, AS, nr-axSpA, and GCA, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatology/dosing-lab-monitoring#:~:text=RINVOQ%20is%20a%2015%20mg,not%20split%2C%20crush%2C%20or%20chew)

## Taking treatment

<a id="rinvoq-tablet-residue"></a>

### What should be done if RINVOQ tablet residue appears in the stool?

> “Reports of medication residue in stool or ostomy output have occurred in patients taking RINVOQ. Most reports described anatomic or functional GI conditions with shortened GI transit times. Instruct patients to contact their healthcare provider if medication residue is observed repeatedly. Monitor patients clinically and consider alternative treatment if there is an inadequate therapeutic response.”

Source: [RINVOQ: RINVOQ® (upadacitinib) Dosing for RA, PsA, AS, nr-axSpA, and GCA, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatology/dosing-lab-monitoring#:~:text=Reports%20of%20medication%20residue%20in,is%20an%20inadequate%20therapeutic%20response.)

## Before treatment

<a id="rinvoq-vaccinations"></a>

### Before starting RINVOQ, which vaccines should patients get?

> “Prior to initiating RINVOQ, patients should be brought up to date on all immunizations, including prophylactic varicella zoster or herpes zoster vaccinations, in agreement with current immunization guidelines.”

Source: [RINVOQ: RINVOQ® (upadacitinib) Dosing for RA, PsA, AS, nr-axSpA, and GCA, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatology/dosing-lab-monitoring#:~:text=Prior%20to%20initiating%20RINVOQ%2C%20patients,agreement%20with%20current%20immunization%20guidelines.)

<a id="rinvoq-live-vaccines"></a>

### Can RINVOQ patients receive live vaccines?

> “Avoid use of live vaccines during, or immediately prior to, RINVOQ therapy.”

Source: [RINVOQ: RINVOQ® (upadacitinib) Dosing for RA, PsA, AS, nr-axSpA, and GCA, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatology/dosing-lab-monitoring#:~:text=Avoid%20use%20of%20live%20vaccines%20during%2C%20or%20immediately%20prior%20to%2C%20RINVOQ%20therapy.)

## Related pages
- [Medical information: Rinvoq (upadacitinib): Rheumatoid arthritis](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis)
- [Indication](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/drug-interactions)
- [Storage and supply](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/access-and-coverage)
